PDS Biotechnology Corporation (PDSB) analyst actions
Rating and price-target actions on PDSB in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PDSB overview →
2 measured PDSB analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer | Press release | -1.49% | -13.38% | |
| PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Press release | -1.24% | -0.62% |
Keep exploring
More PDSB: earnings → · SEC filings → · PDSB overview →